CN113382731A - 包含tno155和瑞博西尼的药物组合 - Google Patents

包含tno155和瑞博西尼的药物组合 Download PDF

Info

Publication number
CN113382731A
CN113382731A CN202080012520.8A CN202080012520A CN113382731A CN 113382731 A CN113382731 A CN 113382731A CN 202080012520 A CN202080012520 A CN 202080012520A CN 113382731 A CN113382731 A CN 113382731A
Authority
CN
China
Prior art keywords
day
amino
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080012520.8A
Other languages
English (en)
Chinese (zh)
Inventor
Y-N·P·陈
郝淮湘
刘晨
M·莫塞尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113382731A publication Critical patent/CN113382731A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080012520.8A 2019-02-12 2020-02-10 包含tno155和瑞博西尼的药物组合 Pending CN113382731A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804708P 2019-02-12 2019-02-12
US62/804,708 2019-02-12
PCT/IB2020/051031 WO2020165734A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Publications (1)

Publication Number Publication Date
CN113382731A true CN113382731A (zh) 2021-09-10

Family

ID=69724013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080012520.8A Pending CN113382731A (zh) 2019-02-12 2020-02-10 包含tno155和瑞博西尼的药物组合

Country Status (14)

Country Link
US (1) US12343344B2 (cg-RX-API-DMAC7.html)
EP (1) EP3923941B1 (cg-RX-API-DMAC7.html)
JP (1) JP7493521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210126653A (cg-RX-API-DMAC7.html)
CN (1) CN113382731A (cg-RX-API-DMAC7.html)
AU (3) AU2020222296B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127286A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002099A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063733T3 (cg-RX-API-DMAC7.html)
IL (1) IL284835B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009563A (cg-RX-API-DMAC7.html)
TW (1) TWI831916B (cg-RX-API-DMAC7.html)
WO (1) WO2020165734A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
EP3923940B1 (en) * 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
CN117642167A (zh) * 2021-05-05 2024-03-01 沪亚生物国际有限责任公司 Shp2抑制剂单一疗法及其用途
CN117177752A (zh) * 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
TWI852912B (zh) * 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3123850A1 (en) 2018-12-17 2020-06-25 Lunella Biotech, Inc. Triple combination therapies for anti-aging
PE20211551A1 (es) 2018-12-17 2021-08-16 Lunella Biotech Inc Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN113382774A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合

Also Published As

Publication number Publication date
IL284835A (en) 2021-08-31
EP3923941A1 (en) 2021-12-22
JP7493521B2 (ja) 2024-05-31
CA3127286A1 (en) 2020-08-20
EP3923941B1 (en) 2025-12-03
US20220160707A1 (en) 2022-05-26
MX2021009563A (es) 2021-09-08
US12343344B2 (en) 2025-07-01
AU2020222296A1 (en) 2021-08-05
AU2020222296B2 (en) 2023-04-06
WO2020165734A1 (en) 2020-08-20
BR112021015632A2 (pt) 2021-10-05
JP2022519375A (ja) 2022-03-23
AU2023203751A1 (en) 2023-07-13
IL284835B1 (en) 2025-04-01
TWI831916B (zh) 2024-02-11
CL2021002099A1 (es) 2022-04-18
ES3063733T3 (en) 2026-04-20
AU2025203816A1 (en) 2025-06-12
KR20210126653A (ko) 2021-10-20
IL284835B2 (en) 2025-08-01
TW202045171A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
JP7572958B2 (ja) Tno155及びkrasg12c阻害剤を含む医薬組合せ
US11298362B2 (en) Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
JP2025529199A (ja) がんの治療で使用するためのdcc-3116とmapkap経路阻害剤との併用
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060474

Country of ref document: HK